Apheresis
Conditions
Brief summary
Rate of lipoprotein apheresis sessions performed over 52 weeks normalized to the weekly lipoprotein apheresis schedule
Detailed description
Time to lipoprotein apheresis avoidance (where lipoprotein apheresis avoidance is defined as at least 24 weeks of no lipoprotein apheresis until end of study), Total avoidance of lipoprotein apheresis from week 12 to week 52, Change from baseline to week 52 in the log-transformed Lp(a) (measured prior to planned lipoprotein apheresis)
Interventions
Sponsors
Novartis Pharma AG
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Rate of lipoprotein apheresis sessions performed over 52 weeks normalized to the weekly lipoprotein apheresis schedule | — |
Secondary
| Measure | Time frame |
|---|---|
| Time to lipoprotein apheresis avoidance (where lipoprotein apheresis avoidance is defined as at least 24 weeks of no lipoprotein apheresis until end of study), Total avoidance of lipoprotein apheresis from week 12 to week 52, Change from baseline to week 52 in the log-transformed Lp(a) (measured prior to planned lipoprotein apheresis) | — |
Countries
Germany
Outcome results
None listed